Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise

KELOWNA, BC, Jan. 12, 2026 /PRNewswire/ — Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) („Doseology“ or the „Company“) a leader in biotechnology-driven consumer products, today announced a strategic partnership with McKinney Regulatory Science Advisors („McKinney„), a premier FDA regulatory consulting firm specializing in nicotine and reduced-risk consumer products, to spearhead its regulatory submission strategy and solidify its commitment to scientific leadership in the oral pouch technology space.

This collaboration marks a pivotal advancement for Doseology, transitioning the Company towards regulatory execution and commercial readiness. McKinney’s comprehensive guidance will encompass formulation strategy, data generation, Pre-market Tobacco Product Application („PMTA„) preparation, and post-market compliance. The aim is to position Doseology as a frontrunner in delivering differentiated, IP and/or trade secret protected oral pouch products to regulated markets with confidence.